JAMES W. HAVILAND, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Although the field of antibiotics is developing so rapidly as to render it almost kaleidoscopic, during recent months several topics of general interest have come into sharp focus. The subject of first consideration will include not only new drugs but also new forms of old drugs, as well as old drugs. Beyond this, I shall confine my discussion to two main items, bacterial resistance to antibiotics, and antibiotic toxicity.
Erythromycin (Ilotycin,† Erythrocin,‡) presently holds first place of interest in the evaluation of new antibiotics. Its history is a matter of record.1 Although it seems to be
HAVILAND JW. ADVANCES IN ANTIBIOTIC THERAPY*. Ann Intern Med. 1953;39:307–317. doi: https://doi.org/10.7326/0003-4819-39-2-307
Download citation file:
Published: Ann Intern Med. 1953;39(2):307-317.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use